Incannex’s CBD Chewing Gum Offers Hope for Smokers Looking to Quit
    Incannex’s CBD Chewing Gum Offers Hope for Smokers Looking to Quit
    PRISM Latest

    February 23, 2024 - by Catie Corcoran

    Incannex’s CBD Chewing Gum Offers Hope for Smokers Looking to Quit

    23 February 2024

    New York, February 23, 2024 - PRISM MarketView - Leading cannabinoid and psychedelic medicine company, Incannex Healthcare (Nasdaq: IXHL), has completed a pre-IND (Investigational New Drug) meeting with the FDA regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse.
    Incannex Healthcare Limited - Prism MarketView

    Incannex Healthcare Limited - Prism MarketView

    Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine th

    Read More

    Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation - Prism MarketView

    Incannex HealthcareMELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic...

    Read More

    CannQuit-N is a smoking cessation chewing gum that combines controlled-release of cannabidiol (CBD) with nicotine. The combination of CBD and nicotine is hypothesized to better assist addicted smokers to quit smoking than traditional nicotine containing chewing gum.
    Incannex said that the productive discussion with the FDA is an important milestone for the development of CannQuit-N and will guide the continued development of the drug product.
    Highlights
    Incannex holds granted patents on chewing gums that combine CBD and nicotine.
    Medicated chewing gums deliver their active ingredients directly into the circulation of the oral mucosa, ensuring that the effects of the ingredients are delivered rapidly, but also in a sustained manner to reduce cravings for longer than other delivery methods.
    The total economic cost of smoking in the US is estimated at more than US$300 billion per annum and is responsible for more than 480,000 deaths per year in the US.
    About Incannex Healthcare Inc.
    Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
    U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.
    Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patent applications.
    PRISM MarketView does not provide investment advice.
    Media Contact
    Company Name: Prism MarketView
    Email: info@prismmarketview.com
    Phone: 646-863-6341
    Website: https://prismmarketview.com
    To see this content properly accept cookies.
    PRISM MarketView Social Media
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.